Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAYLA M BERGMANN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730143645
CMS profile
214770
Location
BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$17,392.19

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $15,460.60 13
Genentech USA, Inc. $1,841.56 2
GlaxoSmithKline, LLC. $49.62 3
PFIZER INC. $40.41 4

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAYLA M BERGMANN

NPI 1730143645 · CMS profile ID 214770

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730143645?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730143645?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730143645?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1730143645?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $17,392.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $16.2412/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738828093 CMS
Genentech USA, Inc. $1,735.0011/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743107531 CMS
PFIZER INC. $10.2610/02/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743812969 CMS
PFIZER INC. $11.2410/02/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743812971 CMS
PFIZER INC. $13.2510/02/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743813095 CMS
PFIZER INC. $5.6610/02/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743813097 CMS
Novo Nordisk Inc $1,700.0008/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744975867 CMS
GlaxoSmithKline, LLC. $17.1407/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738688553 CMS
Novo Nordisk Inc $1,700.0007/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744880045 CMS
Novo Nordisk Inc $1,700.0007/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745055113 CMS
GlaxoSmithKline, LLC. $16.2406/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738834521 CMS
Novo Nordisk Inc $1,360.0005/29/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744719591 CMS
Novo Nordisk Inc $1,700.0005/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744691059 CMS
Novo Nordisk Inc $1,700.0004/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744877829 CMS
Novo Nordisk Inc $289.0004/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745049757 CMS
Novo Nordisk Inc $3,825.0002/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744579341 CMS
Novo Nordisk Inc $60.9502/13/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744579343 CMS
Novo Nordisk Inc $149.4502/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744579345 CMS
Novo Nordisk Inc $178.0802/13/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744579347 CMS
Novo Nordisk Inc $526.7202/13/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744579349 CMS
Novo Nordisk Inc $571.4002/13/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744579351 CMS
Genentech USA, Inc. $106.5601/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743107527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,400.59 36
PY2020 $17,392.19 22
PY2021 $28,307.86 31
PY2022 $56,578.29 50
PY2023 $25,272.75 24
PY2024 $93,551.59 58
PY2025 $32,786.96 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,096.67 57
PY2024 Recipient $330.00 1
PY2024 Principal investigator $123,216.25 29
PY2023 Recipient $7,690.97 4
PY2023 Principal investigator $204,898.80 60
PY2022 Recipient $2,500.00 1
PY2022 Principal investigator $196,214.82 57
PY2021 Principal investigator $297,011.90 78
PY2020 Principal investigator $507,163.73 79
PY2019 Recipient $14,782.04 33
PY2019 Principal investigator $370,237.09 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $112.97 12/27/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics ofCSL889in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348179
Principal investigator 1 Global Blood Therapeutics, Inc. $32,175.00 12/21/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPEN LABEL, OBSERVATIONAL, PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE (SCD) TREATED WITH OXBRYTA (VOXELOTOR). No dispute reported 06/30/2026 914607589
Principal investigator 1 CSL Behring $1,324.64 12/08/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics ofCSL889in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348177
Principal investigator 1 CSL Behring $399.43 12/07/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics ofCSL889in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348175
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,290.60 11/23/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937178743
Principal investigator 1 Global Blood Therapeutics, Inc. $1,800.00 11/08/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT_440-041_3939_01 No dispute reported 06/30/2026 914607601
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,354.50 11/07/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937177443
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $190.60 11/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937177215
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 10/10/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 937175523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $715.00 10/10/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 937175525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 10/10/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 937175527
Principal investigator 1 CSL Behring $1,150.75 10/04/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348173
Principal investigator 1 Global Blood Therapeutics, Inc. $6,084.00 09/21/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPEN LABEL, OBSERVATIONAL, PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE (SCD) TREATED WITH OXBRYTA (VOXELOTOR). No dispute reported 06/30/2026 914607583
Principal investigator 1 CSL Behring $165.19 09/07/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348171
Recipient PFIZER INC. $2,500.00 09/07/2022 Covered Recipient Physician A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 949787021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $209.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937173281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $63.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937173283
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937173285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937173287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,074.30 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937173289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937173353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937173355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,050.00 09/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937173357
Principal investigator 1 CSL Behring $181.58 07/13/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348169
Principal investigator 1 CSL Behring $748.80 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348133
Principal investigator 1 CSL Behring $1,482.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348135
Principal investigator 1 CSL Behring $2,500.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348137
Principal investigator 1 CSL Behring $3,575.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348139
Principal investigator 1 CSL Behring $4,875.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348141
Principal investigator 1 CSL Behring $12,402.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348143
Principal investigator 1 CSL Behring $875.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348145
Principal investigator 1 CSL Behring $2,500.00 07/06/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348159
Principal investigator 1 Global Blood Therapeutics, Inc. $8,035.00 07/05/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT_440-041_3939_01 No dispute reported 06/30/2026 914607595
Principal investigator 1 CSL Behring $186.64 06/22/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348167
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,365.00 06/17/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937170291
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,045.00 06/17/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937170293
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 06/17/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937170295
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,711.56 06/15/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER, STUDY TO ASSESS EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB), IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM No dispute reported 06/30/2026 909407161
Principal investigator 1 CSL Behring $167.48 05/25/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348165
Principal investigator 1 Global Blood Therapeutics, Inc. $2,742.00 05/20/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBA002_GBT440-032_80036131 No dispute reported 06/30/2026 914607619
Principal investigator 1 CSL Behring $2,943.52 05/18/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348163
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,772.00 05/04/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937167761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,101.10 05/02/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937167553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,033.00 04/04/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937166049
Principal investigator 1 CSL Behring $53.00 03/23/2022 Non-covered Recipient Entity
Medical Univ Of South Carolina - Comprehensive Sickle Cell Clinic
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940344761
Principal investigator 1 CSL Behring $21.20 03/23/2022 Non-covered Recipient Entity
Medical Univ Of South Carolina - Comprehensive Sickle Cell Clinic
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940344763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $202.40 03/14/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 937164885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,817.00 03/10/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937164715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.00 03/10/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 937164717
Principal investigator 1 Global Blood Therapeutics, Inc. $8,464.00 03/09/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBA002_GBT440-032_80036131 No dispute reported 06/30/2026 914607613
Principal investigator 1 CSL Behring $3,647.42 03/04/2022 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease No dispute reported 06/30/2026 940348161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $257.80 03/04/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 937164377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,996.00 02/23/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937163853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 02/23/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 937163855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,262.00 01/19/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937161947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,560.00 01/19/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937161949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,170.00 01/19/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937161951
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,622.34 01/06/2022 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRIS No dispute reported 06/30/2026 909407143